David M Davies
Overview
Explore the profile of David M Davies including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1003
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Parente-Pereira A, Whilding L, Brewig N, van der Stegen S, Davies D, Wilkie S, et al.
J Immunol
. 2013 Jul;
191(5):2437-45.
PMID: 23898037
Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy, underscoring the need for better therapies. Adoptive immunotherapy using genetically targeted T cells represents a promising new treatment for hematologic...
22.
Wilkie S, van Schalkwyk M, Hobbs S, Davies D, van der Stegen S, Parente Pereira A, et al.
J Clin Immunol
. 2012 Apr;
32(5):1059-70.
PMID: 22526592
Purpose: Chimeric antigen receptor (CAR) engineered T-cells occupy an increasing niche in cancer immunotherapy. In this context, CAR-mediated CD3ζ signaling is sufficient to elicit cytotoxicity and interferon-γ production while the...
23.
Davies D, Foster J, van der Stegen S, Parente-Pereira A, Chiapero-Stanke L, Delinassios G, et al.
Mol Med
. 2012 Feb;
18:565-76.
PMID: 22354215
Pharmacological targeting of individual ErbB receptors elicits antitumor activity, but is frequently compromised by resistance leading to therapeutic failure. Here, we describe an immunotherapeutic approach that exploits prevalent and fundamental...
24.
Wilkie S, Burbridge S, Chiapero-Stanke L, Pereira A, Cleary S, van der Stegen S, et al.
J Biol Chem
. 2010 Jun;
285(33):25538-44.
PMID: 20562098
Polyclonal T-cells can be directed against cancer using transmembrane fusion molecules known as chimeric antigen receptors (CARs). Although preclinical studies have provided encouragement, pioneering clinical trials using CAR-based immunotherapy have...
25.
Wilkie S, Picco G, Foster J, Davies D, Julien S, Cooper L, et al.
J Immunol
. 2008 Mar;
180(7):4901-9.
PMID: 18354214
MUC1 is a highly attractive immunotherapeutic target owing to increased expression, altered glycosylation, and loss of polarity in >80% of human cancers. To exploit this, we have constructed a panel...